Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Trial details
- Registry ID
- NCT06736574
- Drugs studied
- Omecamtiv Mecarbil (OM)
TrialRedline tracks 10 clinical trials sponsored by Cytokinetics: 6 Phase 3, 2 Phase 2 / 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMNCT04848506 | Aficamten (5 - 20 mg) | Enrolling by invitation | 2029-03Estimated |
| A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).NCT06412666 | Aficamten | Active not recruiting | 2030-01Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFNCT06793371 | CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) | Recruiting | 2026-09Estimated |
| Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic CardiomyopathyNCT04219826 | CK-3773274 (10 - 30 mg), CK-3773274 (5 - 15 mg) | Completed | 2023-02-28Actual |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Adverse Events (AEs) Time frame: Baseline to End of study, up to 5 years. After: Measure: Incidence of adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Adverse Events (AEs) Time frame: Baseline to End of study, up to 5 years Measure: Incidence of serious adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Serious Adverse Events (SAEs) Time frame: Baseline to End of study, up to 5 years Measure: Incidence of left ventricular ejection fraction (LVEF) < 50% observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported LVEF \<50% Time frame: Baseline to End of study, up to 5 years.
Before: Mar 2028. After: Mar 2029.
Before: Estimated. After: Actual.
Before: Aug 2026. After: 31 Aug 2026.
Before: 55 participants (planned). After: 65 participants (planned).
Before: Recruiting. After: Active not recruiting.
Before: Jun 2026. After: Aug 2026.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET). After: Measure: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET). After: Measure: Change From Baseline in pVO2 at Week 24.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of adverse events observed during dosing of CK--3773274 in patients with HCM. After: Measure: Incidence of Adverse Events (AEs) Measure: Incidence of Left Ventricular Ejection Fraction (LVEF) < 50% Measure: Incidence of Serious Adverse Events (SAEs).